Parma, Italy

Riccardo Patacchini

USPTO Granted Patents = 1 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2010

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Riccardo Patacchini: Innovator in Respiratory Disease Treatment

Introduction

Riccardo Patacchini is a notable inventor based in Parma, Italy. He has made significant contributions to the field of medicinal chemistry, particularly in the development of treatments for respiratory diseases. His innovative work has led to the creation of a patent that addresses critical health issues.

Latest Patents

Patacchini holds a patent for "Quinuclidine derivatives as M3 antagonists." This patent involves quinuclidine derivatives of the general formula (I) in the form of single enantiomers or mixtures thereof. These compounds are useful in the manufacture of a medicament for the prevention and therapy of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, cough, and emphysema. He has 1 patent to his name.

Career Highlights

Riccardo Patacchini is associated with Chiesi Farmaceutici S.p.A., a company known for its commitment to developing innovative pharmaceutical solutions. His work at Chiesi has allowed him to focus on creating effective treatments that improve the quality of life for patients suffering from respiratory conditions.

Collaborations

Throughout his career, Patacchini has collaborated with talented individuals such as Gabriele Amari and Andrea Rizzi. These collaborations have fostered a productive environment for innovation and have contributed to the advancement of respiratory therapies.

Conclusion

Riccardo Patacchini's contributions to the field of medicinal chemistry, particularly through his patent on quinuclidine derivatives, highlight his commitment to addressing respiratory diseases. His work continues to impact the pharmaceutical industry positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…